Immunomedics, Inc. (IMMU) Reports Final Efficacy Results Of Phase Ib Trial With Yttrium-90-Labeled Clivatuzumab Tetraxetan In Patients With Metastatic Pancreatic Cancer
6/2/2014 9:47:50 AM
CHICAGO, June 1, 2014 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today reported an overall disease response rate of 41%, including 2 patients (7%) with partial response and 10 patients (34%) with stable disease as best response, in 29 patients with relapsed/refractory, metastatic pancreatic cancer treated with the investigational pancreatic cancer therapeutic, clivatuzumab tetraxetan labeled with yttrium-90 (90Y), in combination with low-dose gemcitabine as a radiosensitizer. This was compared to a control group of 29 similar patients who received 90Y-clivatuzumab tetraxetan without low-dose gemcitabine. Treatment responses were assessed by computed tomography (CT) based on RECIST criteria.
Help employers find you! Check out all the jobs and post your resume.
comments powered by